Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868967 | 0.78 | KDM4E (0.39) | KDM4E | |
| SCHEMBL481337 | 0.78 | HTR2A (0.54) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL14029780 | 0.77 | SMPD1 (0.46) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL1067850 | 0.74 | HTR2A (0.68) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL29528198 | 0.74 | HTR2A (0.68) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL7485407 | 0.73 | HTR2A (0.53) | HTR2AHTR2CHTR2BKDM4E | |
| Hydrochloric Acid SCHEMBL29386152 | 0.73 | HTR2A (0.66) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL22614745 | 0.73 | HTR2A (0.66) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL28211962 | 0.73 | HTR2A (0.50) | HTR2AHTR2CHTR2BHTR1ACYP1A2 | |
| SCHEMBL7059305 | 0.72 | HTR2A (0.56) | HTR2AHTR2CHTR2BHTR1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008313-B2 | Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC | 2011-03-31 | — | — | US | disclosed |
| US-7858632-B2 | Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine | ROCHE PALO ALTO LLC (US) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | HTR2A 833/4885HTR2C 1025/4885HTR2B 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.